Amyloid Precursor Protein Processing Through a Novel Pathway in Alzheimer's Disease
About the Research Project
Program
Award Type
Standard
Award Amount
$300,000
Active Dates
July 01, 2025 - June 30, 2028
Grant ID
A2025019S
Goals
We aim to study the metabolism of APP fragments generated by the novel eta-secretase pathway to determine if there are changes in AD and to help us form a comprehensive model of APP processing.
Summary
Although APP, the parent protein of Abeta, was discovered 40 years ago, it wasn’t until recently that a new cleavage product of APP was detected in human biofluids. Eta-secretase was found to cut APP to generate AETA. AETA has been shown to be very important in processes that play a role in memory formation, and its levels change in mouse models when prospective AD therapies are administered. Not much is known about AETA in humans, and thus, we want to develop a method to measure how quickly AETA is produced and cleared in a healthy older human and then compare this to AETA metabolism in AD.
Unique and Innovative
The eta-secretase pathway of APP was discovered only 10y ago. Recent reports indicate that a resulting cleavage product, AETA, has an important biological function. There are only a handful of studies reporting the existence of eta-secretase-APP cleavage products in human biofluids, and that AETA levels change in AD in tests of a handful of subjects. In our study, we will not only study whether there are changes in AETA in AD in a larger cohort of 50 subjects, but we will also measure the production and clearance of AETA, thus providing us with more information on the dynamic processing of APP.
Foreseeable Benefits
AETA has been found to be higher during BACE inhibitor treatment. BACE inhibitor clinical trials failed due to cognitive worsening, but attempts to revitalize these drugs in low-dose forms as a preventative strategy for AD are ongoing. Given the potential that AETA might contribute to BACE inhibitor-related adverse effects, it is extremely important to study normal and AD-related AETA metabolism in humans, which, until now, no one has done. Our results could be informative for future low-dose BACE inhibitor trial programs and give us a better understanding of the complex processing of APP.
Related Grants
Alzheimer's Disease Research
Linking Plaque Shapes to Amyloid Structures in Alzheimer’s Disease
Active Dates
July 01, 2025 - June 30, 2027
Principal Investigator
Anllely Fernandez, PhD
Current Organization
Indiana University
Linking Plaque Shapes to Amyloid Structures in Alzheimer’s Disease
Active Dates
July 01, 2025 - June 30, 2027
Principal Investigator
Anllely Fernandez, PhD
Current Organization
Indiana University
Alzheimer's Disease Research
Exploring the Origin and Composition of a Unique Pathology in Alzheimer's Disease
Active Dates
July 01, 2025 - June 30, 2028
Principal Investigator
Cyril Pottier, PhD
Current Organization
Washington University in St.Louis
Exploring the Origin and Composition of a Unique Pathology in Alzheimer's Disease
Active Dates
July 01, 2025 - June 30, 2028
Principal Investigator
Cyril Pottier, PhD
Current Organization
Washington University in St.Louis
Alzheimer's Disease Research
Increase of ADAM10 Protein Expression in the Brain as an Alzheimer’s Disease Therapeutic
Active Dates
July 01, 2024 - June 30, 2027
Principal Investigator
Jaehong Suh, PhD
Current Organization
Massachusetts General Hospital
Increase of ADAM10 Protein Expression in the Brain as an Alzheimer’s Disease Therapeutic
Active Dates
July 01, 2024 - June 30, 2027
Principal Investigator
Jaehong Suh, PhD
Current Organization
Massachusetts General Hospital